ABLE下肢机器人外骨骼用于脊髓损伤患者的多中心安全性与可行性研究
本研究为德国和西班牙两个脊髓损伤中心的前瞻性前测-后测准实验研究,24名脊髓损伤患者接受12次ABLE外骨骼训练与评估,并在4周后随访。242次训练中报告8例器械相关不良事件(疼痛和皮肤损伤),穿脱总时间6:50±2:50分钟,所有参与者辅助水平和步态参数改善(p<0.05),设备心理社会影响积极且满意度良好。
要点
- 24名脊髓损伤患者完成12次ABLE外骨骼训练及4周随访,242次训练中报告8例器械相关不良事件。
- 穿脱总时间6:50±2:50分钟,所有参与者辅助水平和步态参数(时间、步数、距离、速度)改善(p<0.05)。
- 设备心理社会影响积极,参与者和治疗师满意度良好,安全性(参与者)和重量(治疗师)评分最佳。
核心结论
- ABLE外骨骼在医院环境中对脊髓损伤患者进行安全步态训练具有可行性,训练后临床结局改善。
- 研究方案允许与其他外骨骼试验结果进行一致比较,可作为早期临床评估标准化的未来框架。
研究设计与样本
- 前瞻性前测-后测准实验研究,在德国和西班牙两个脊髓损伤中心开展。
- 招募24名脊髓损伤住院和门诊患者,年龄45±12岁,损伤节段C5至L3,ASIA损伤量表A至D,主要为亚急性期(损伤后<1年)。
- 采用12次训练与评估方案,使用ABLE外骨骼,并包含4周后随访 visit 以评估训练后结局。
主要发现
- 24名参与者全部完成随访;242次训练中报告8例器械相关不良事件(疼痛和皮肤损伤)。
- 穿脱总时间为6:50±2:50分钟。
- 所有参与者的辅助水平和步态参数(时间、步数、距离和速度)均改善(p<0.05)。
- 研究开始时能借助设备(n=9)和不借助设备(n=6)完成步行测试的参与者,步行功能和RPE均改善(p<0.05)。
- 报告了外骨骼积极的心理社会影响,设备满意度良好,参与者在安全性方面评分最佳,治疗师在重量方面评分最佳,双方在耐用性和尺寸方面评分最佳。
关键数值与推荐
- 安全性结局包括器械相关不良事件和退出数量,每次训练均记录。
- 可行性与可用性指标包括辅助水平、穿脱时间,同时记录步态参数和功能变化。
- 患者报告结局包括感知用力率(RPE)和设备心理社会影响,并在参与者和治疗师中评估设备满意度。
临床怎么用
- 对于C5至L3、ASIA A至D的脊髓损伤患者,可在医院环境中使用ABLE外骨骼进行安全步态训练。
- 训练过程中需监测器械相关不良事件,重点关注疼痛和皮肤损伤。
- 穿脱时间约6:50±2:50分钟,可作为临床流程安排参考。
局限性
- 研究为非随机准实验设计,样本量24例,主要纳入亚急性期脊髓损伤患者。
- 原文未报告对照组或盲法设置。
- 原文未报告长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic lower-limb exoskeletons have the potential to provide additional clinical benefits for persons with spinal cord injury (SCI). However, high variability between protocols does not allow the comparison of study results on safety and feasibility between different exoskeletons. We therefore incorporated key aspects from previous studies into our study protocol and accordingly conducted a multicentre study investigating the safety, feasibility and usability of the ABLE Exoskeleton in clinical settings. METHODS: In this prospective pretest-posttest quasi-experimental study across two SCI centres in Germany and Spain, in- and outpatients with SCI were recruited into a 12-session training and assessment protocol, utilising the ABLE Exoskeleton. A follow-up visit after 4 weeks was included to assess after-training outcomes. Safety outcomes (device-related adverse events (AEs), number of drop-outs), feasibility and usability measures (level of assistance, donning/doffing-time) were recorded at every session together with changes in gait parameters and function. Patient-reported outcome measures including the rate of perceived exertion (RPE) and the psychosocial impact of the device were performed. Satisfaction with the device was evaluated in both participants and therapists. RESULTS: All 24 participants (45 ± 12 years), with mainly subacute SCI (< 1 year after injury) from C5 to L3, (ASIA Impairment Scale A to D) completed the follow-up. In 242 training sessions, 8 device-related AEs (pain and skin lesions) were reported. Total time for don and doff was 6:50 ± 2:50 min. Improvements in level of assistance and gait parameters (time, steps, distance and speed, p < 0.05) were observed in all participants. Walking function and RPE improved in participants able to complete walking tests with (n = 9) and without (n = 6) the device at study start (p < 0.05). A positive psychosocial impact of the exoskeleton was reported and the satisfaction with the device was good, with best ratings in safety (participants), weight (therapists), durability and dimensions (both). CONCLUSIONS: Our study results prove the feasibility of safe gait training with the ABLE Exoskeleton in hospital settings for persons with SCI, with improved clinical outcomes after training. Our study protocol allowed for consistent comparison of the results with other exoskeleton trials and can serve as a future framework towards the standardisation of early clinical evaluations. Trial Registration https://trialsearch.who.int/ , DRKS00023503, retrospectively registered on November 18, 2020.
引用
- Wright MA, Herzog F, Mas-Vinyals A, et al. Multicentric investigation on the safety, feasibility and usability of the ABLE lower-limb robotic exoskeleton for individuals with spinal cord injury: a framework towards the standardisation of clinical evaluations. J Neuroeng Rehabil. 2023. PMID: 37046307. doi:10.1186/s12984-023-01165-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。